Opana ER Related Published Studies
Well-designed clinical trials related to Opana ER (Oxymorphone)
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
Comparison of the analgesic efficacy of hydromorphone and oxymorphone in dogs and cats: a randomized blinded study. [2008.07]
Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial. [2007.06]
Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Double-blind, Placebo-controlled Study. [2007.02]
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. [2007.01]
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. [2006.03]
Effects of oxymorphone and hydromorphone on the minimum alveolar concentration of isoflurane in dogs. [2006.01]
Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial. [2005.12]
Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial. [2005.09]
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. [2005.03]
Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. [2005.01]
Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. [2005]
The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. [2004.11]
Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. [2004.07]
Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. [2004.06]
Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. [2004.04]
Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs. [2004.04]
Comparison of the effects of buprenorphine, oxymorphone hydrochloride, and ketoprofen for postoperative analgesia after onychectomy or onychectomy and sterilization in cats. [2002.11]
Effects of hydromorphone or oxymorphone, with or without acepromazine, on preanesthetic sedation, physiologic values, and histamine release in dogs. [2001.04.01]
Cardiovascular effects of epidurally administered oxymorphone and an oxymorphone-bupivacaine combination in halothane-anesthetized dogs. [1999.02]
End tidal halothane concentration and postoperative analgesia requirements in dogs: a comparison between intravenous oxymorphone and epidural bupivacaine alone and in combination with oxymorphone. [1998.06]
Comparison of ketoprofen, oxymorphone hydrochloride, and butorphanol in the treatment of postoperative pain in dogs. [1997.08.15]
A comparison of ketorolac with flunixin, butorphanol, and oxymorphone in controlling postoperative pain in dogs. [1996.09]
Ability of flumazenil, butorphanol, and naloxone to reverse the anesthetic effects of oxymorphone-diazepam in dogs. [1996.08.15]
Postoperative analgesic and cardiopulmonary effects in dogs of oxymorphone administered epidurally and intramuscularly, and medetomidine administered epidurally: a comparative clinical study. [1996.07]
Butorphanol tartrate for partial reversal of oxymorphone-induced postoperative respiratory depression in the dog. [1994.01]
Narcotic-induced histamine release: a comparison of morphine, oxymorphone, and fentanyl infusions. [1991.10]
An evaluation of morphine and oxymorphone administered via patient-controlled analgesia (PCA) or PCA plus basal infusion in postcesarean-delivery patients. [1989.10]
A comparison of morphine, meperidine, and oxymorphone as utilized in patient-controlled analgesia following cesarean delivery. [1989.04]
A comparison of oxymorphone and fentanyl as narcotic supplements in general anesthesia. [1989]
Well-designed clinical trials possibly related to Opana ER (Oxymorphone)
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. [2009.06]
The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. [2009.04]
Voriconazole drastically increases exposure to oral oxycodone. [2009.03]
The effect of single-dose tramadol on oxycodone clearance. [2007.11]
A synthetic fraction of feline facial pheromones calms but does not reduce struggling in cats before venous catheterization. [2006.07]
Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. [2006]
Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs. [2004.01]
Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. [2001.05]
Assessing the efficacy of perioperative carprofen administration in dogs undergoing surgical repair of a ruptured cranial cruciate ligament. [2000.09]
Morphine or oxycodone in cancer pain? [2000]
Comparison of ketoprofen and carprofen administered prior to orthopedic surgery for control of postoperative pain in dogs. [1999.10.15]
Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. [1998.12]
A comparison of ketorolac tromethamine/oxycodone versus patient-controlled analgesia with morphine in anterior cruciate ligament reconstruction patients. [1998.11]
Pharmacokinetics and pharmacodynamics of controlled-release opioids. [1997.01]
Epidural administration of bupivacaine, morphine, or their combination for postoperative analgesia in dogs. [1996.08.01]
Does naloxone cause a positive urine opiate screen? [1994.12]
Evaluation of anesthetic protocols for neutering 6- to 14-week-old pups. [1994.07.15]
Cardiorespiratory effects of four opioid-tranquilizer combinations in dogs. [1994.07]
Analgesia in dogs after intercostal thoracotomy: a clinical trial comparing intravenous buprenorphine and interpleural bupivacaine. [1994.07]
Respiratory effects and tolerability of Mr 2264 Cl. A new opiate partial agonist in comparison with morphine and placebo. [1994]
The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. [1992.06]
Epidural analgesia during and after cesarean delivery. Comparison of five opioids. [1991.03]
Subcutaneous-PCA: an alternative to IV-PCA for postoperative pain management. [1990.12]
Outpatient premedication: use of midazolam and opioid analgesics. [1989.10]
Other research related to Opana ER (Oxymorphone)
Pharmacokinetics and behavioral effects of an extended-release, liposome-encapsulated preparation of oxymorphone in rhesus macaques. [2009.07]
Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain. [2008.10]
Oxymorphone: a mature molecule with new life. [2008.10]
Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. [2008.05]
Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. [2008.05]
Comparison of the analgesic efficacy of hydromorphone and oxymorphone in dogs and cats: a randomized blinded study. [2008.03.18]
Oral extended-release oxymorphone: a new choice for chronic pain relief. [2007.07]
Oral oxymorphone for pain management. [2007.07]
Use of oral oxymorphone in the elderly. [2007.05]
Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. [2007.04.01]
Evidence that oxymorphone-induced increases in micronuclei occur secondary to hyperthermia. [2007.02]
Oxymorphone: a review. [2006.02]
Evaluation of induction by use of a combination of oxymorphone and diazepam or hydromorphone and diazepam and maintenance of anesthesia by use of isoflurane in dogs with experimentally induced hypovolemia. [2005.07]
GC-MS quantitation of codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone in blood. [2005.07]
Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. [2005.03]
Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. [2005.01]
Evaluation of liposome-encapsulated oxymorphone hydrochloride in mice after splenectomy. [2004.10]
The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue. [2004]
A single dose of liposome-encapsulated oxymorphone or morphine provides long-term analgesia in an animal model of neuropathic pain. [2003.06]
Liposome-encapsulated oxymorphone hydrochloride provides prolonged relief of postsurgical visceral pain in rats. [2003.06]
Comparison of transdermal fentanyl and intramuscular oxymorphone on post-operative behaviour after ovariohysterectomy in dogs. [1998.11]
Antinociceptive effects of oxymorphone-butorphanol-acepromazine combination in cats. [1998.09]
Intranasal absorption of oxymorphone. [1997.08]
Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. [1995.01]
A clinical comparison of oxymorphone-acepromazine and butorphanol-acepromazine sedation in dogs. [1992.09]
Cardiopulmonary and behavioral effects of combinations of acepromazine/butorphanol and acepromazine/oxymorphone in dogs. [1992.06.15]
Epidural vs. intramuscular oxymorphone analgesia after thoracotomy in dogs. [1991.11]
Naloxone reversal of oxymorphone effects in dogs. [1989.11]
Comparison of histamine release induced by morphine and oxymorphone administration in dogs. [1988.10]
Oxymorphone: cardiovascular, pulmonary, and behavioral effects in dogs. [1987.11]
Other possibly related research studies
Extended-duration agents for perioperative pain management. [2007.02]
Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. [2006.10]
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. [2006.05]
Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain. [2006.03]
Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. [2006.03.20]
Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. [2005.05.05]
Pain management in cats--past, present and future. Part 2. Treatment of pain--clinical pharmacology. [2004.10]
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. [2004.04]
Supraspinal antinociceptive effects of mu and delta agonists involve modulation of adenosine uptake. [2003.02]
Clinical pharmacology of opioids for pain. [2002.07]
Results of preemptive epidural administration of morphine with or without bupivacaine in dogs and cats undergoing surgery: 265 cases (1997-1999). [2002.09.01]
Reliability of goniometry in Labrador Retrievers. [2002.07]
A multisite case report on the clinical use of sevoflurane in dogs. [2001.09]
Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. [2001.06]
A comparison of two opioid analgesics for relief of visceral pain induced by intestinal resection in rats. [2001.01]
Leg edema from intrathecal opiate infusions. [2000]
|
